Rezolute to Participate in Upcoming Investor Conferences
Rezolute (NASDAQ: RZLT), a late-stage rare disease company specializing in treatments for hypoglycemia caused by hyperinsulinism, has announced its participation in four upcoming investor conferences in May and June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rezolute (NASDAQ: RZLT), a late-stage rare disease company specializing in treatments for hypoglycemia caused by hyperinsulinism, has announced its participation in four upcoming investor conferences in May and June 2025. The company's management will attend:
- The Citizens JMP Life Sciences Conference (May 7-8)
- H.C. Wainwright BioConnect Investor Conference (May 20)
- Craig-Hallum Institutional Investor Conference (May 28)
- Jefferies Global Healthcare Conference (June 3-5)
Management will be available for one-on-one meetings with investors during these conferences. Interested investors should contact their respective conference representatives to schedule meetings.
Details
News Market Reaction – RZLT
The recorded move for RZLT in the trading session of this news was +5.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Event: The Citizens JMP Life Sciences Conference
Date: May 7-8, 2025
Event: H.C. Wainwright BioConnect Investor Conference
Date: May 20, 2025
Event: Craig-Hallum Institutional Investor Conference
Date: May 28, 2025
Event: Jefferies Global Healthcare Conference
Date: June 3-5, 2025
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their JMP, H.C. Wainwright, Craig-Hallum, and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Media
Sarah Lima
Sarah@GalvinPR.com
(774) 766-0200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.